HOUSTON, April 15, 2019 /PRNewswire/ -- Soliton,
Inc., (NASDAQ: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), today announced
that Dr. Elizabeth Tanzi of
Capital Laser and Skin Care will present preliminary data from
its completed cellulite clinical trial at the SCALE (Symposium for
Cosmetic Advances and Laser Education) conference in Nashville, Tennessee to be held May 9-11, 2019.
The proof of concept study, conducted by Dr. Michael Kaminer at SkinCare Physicians in
Boston, MA, in collaboration with
Dr. Tanzi, was designed to evaluate the safety and efficacy of
Soliton's acoustic pulse device for the reduction of
cellulite. The data presented will reflect results from a
single acoustic pulse treatment, operating at a higher power level
than the Company's RAP device intended for tattoo removal, at the
12-week timepoint. Dr. Tanzi will also review preclinical data that
appears to support what the Company believes may be a new method
for treating cellulite.
Join our more than 200K fans here
to follow the Company: https://soly-investors.com
"There has been a lot of anticipation surrounding the potential
for our technology as a stand-alone treatment for cellulite,"
commented Dr. Chris Capelli,
President and CEO of Soliton, "especially considering the
preclinical data suggesting that our unique acoustic pulses may be
capable of achieving results only thought possible with invasive
therapies. Considering that our technology is non-invasive
and has been well tolerated by our trial participants, our goal has
been to deliver clinically significant results without patient
discomfort or downtime. We believe the upcoming presentation
by Dr. Tanzi will be an important indicator of our progress and
potential."
Drs. Kaminer and Tanzi are members of Soliton's Advisory
Board.
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first planned commercial product is designed to use rapid
pulses of designed acoustic shockwaves in conjunction with existing
lasers to accelerate the removal of unwanted tattoos (RAP device).
In addition, higher energy versions of acoustic pulse devices are
in early stages of development for potential stand-alone treatment
of cellulite and other indications. Both products are
investigational and are not available for sale in the United States.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of Soliton's
acoustic shockwave device to reduce cellulite in the proof of
concept clinical trial. These statements relate to future events,
future expectations, plans and prospects. Although Soliton believes
that the expectations reflected in such forward-looking statements
are reasonable as of the date made, expectations may prove to have
been materially different from the results expressed or implied by
such forward-looking statements. Soliton has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under in our SEC filings,
including under the heading "Item 1A. Risk Factors" in the Form
10-K for year ended December 31, 2018
we filed with the SEC and updated from time to time in our Form
10-Q filings and in our other public filings with the SEC. Any
forward-looking statements contained in this release speak only as
of its date. Soliton undertakes no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/soliton-announces-cellulite-trial-results-to-be-presented-at-national-aesthetics-conference-on-may-11-2019-300831806.html
SOURCE Soliton, Inc.